Scienta Lab is a deeptech company harnessing artificial intelligence to transform the drug discovery and development process in immunology and inflammation.
With its unique and proprietary EVA foundation model dedicated to immune-mediated diseases, Scienta Lab leverages multimodal data to bridge the gap of translational research, accelerate the validation of new therapeutic targets and the development of personalized treatments. The company’s research activities, led in partnership with top-tier academic institutions across Europe, are regularly featured in medical journals and international congresses.
Scienta Lab is based in Biolabs Hôtel Dieu and has been selected amongst the 2023 edition of the Future 40 program which rewards the most promising startups of Station F each year. In December 2023, the company announced a seed round of € 4M from CentraleSupélec Venture and a team of world-class business angels and is thus seeking for top talents to accelerate its development. In June 2025, Scienta Lab was laureate of the EIC Accelerator program, selected as one of the most innovative deeptech startups across Europe, providing a significant funding to the company.
We are a team with diverse backgrounds in AI, Computational Biology, Immunology and pharma industry, with half the company with PhDs. Join us and be a part of our exciting journey to unravel the mysteries of the immune system!
Discover who we are and what we value here.
STATION F Job board is always looking for great talent. Go ahead and send an application!